Tefibazumab

Tefibazumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetClumping factor A
Clinical data
Trade namesAurexis
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6548H10122N1730O2034S44
Molar mass147035.72 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]

It was developed by Inhibitex.[3]

See also

  • MSCRAMM (microbial surface components recognizing adhesive matrix molecules)

References

  1. Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
  2. Pan A, Lorenzotti S, Zoncada A (January 2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-Infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
  3. John JF (October 2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Current Opinion in Molecular Therapeutics. 8 (5): 455–60. PMID 17078388.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.